{"protocolSection":{"identificationModule":{"nctId":"NCT01623622","orgStudyIdInfo":{"id":"HC-58 (SHS) II-1"},"organization":{"fullName":"Asahi Kasei Pharma Corporation","class":"INDUSTRY"},"briefTitle":"Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke","officialTitle":"A Phase 2 Study of HC-58 in Patients With Severe Upper Limb Hemiplegia After Stroke"},"statusModule":{"statusVerifiedDate":"2015-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-07"},"primaryCompletionDateStruct":{"date":"2015-05","type":"ACTUAL"},"completionDateStruct":{"date":"2015-05","type":"ACTUAL"},"studyFirstSubmitDate":"2012-06-18","studyFirstSubmitQcDate":"2012-06-18","studyFirstPostDateStruct":{"date":"2012-06-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-02-13","lastUpdatePostDateStruct":{"date":"2017-02-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Asahi Kasei Pharma Corporation","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to investigate the efficacy and safety of HC-58 in patients with severe upper limb hemiplegia following stroke."},"conditionsModule":{"conditions":["Severe Upper Limb Hemiplegia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":270,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"HC-58 low dose","type":"EXPERIMENTAL","description":"Low dose","interventionNames":["Drug: HC-58"]},{"label":"HC-58 high dose","type":"EXPERIMENTAL","description":"High dose","interventionNames":["Drug: HC-58"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"HC-58","description":"once or more / week","armGroupLabels":["HC-58 high dose","HC-58 low dose"]},{"type":"DRUG","name":"Placebo","description":"once or more / week","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Onset of shoulder hand syndrome","description":"The incidence rate of shoulder hand syndrome","timeFrame":"12 weeks"},{"measure":"Change from Baseline in the modified Barthel index (MBI) and MBI efficiency","description":"MBI efficiency means MBI gain divided by period of administration","timeFrame":"12 weeks"},{"measure":"Change from Baseline in the Fugl-Meyer Assessment (FMA) (upper limb) and FMA efficiency","description":"FMA efficiency means FMA gain divided by period of administration","timeFrame":"12 weeks"}],"secondaryOutcomes":[{"measure":"Pain score by numeric rating scale","timeFrame":"12 weeks"},{"measure":"Swelling asymmetry between hands","timeFrame":"12 weeks"},{"measure":"Discolouration of the skin of the hand","timeFrame":"12 weeks"},{"measure":"Difference in skin temperature between hands","timeFrame":"12 weeks"},{"measure":"Decreased range of motion","timeFrame":"12 weeks"},{"measure":"Radiographic finding of bone","timeFrame":"12 weeks"},{"measure":"Bone metabolic marker","timeFrame":"12 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with severe upper limb hemiplegia after stroke\n* Within 28 days after stroke at enrollment\n\nExclusion Criteria:\n\n* Patients with sensory loss between shoulder and hand on paralyzed side\n* Patients with pain between shoulder and hand on paralysed side which affects medical rehabilitation","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Toshiya Umeda","affiliation":"Asahi Kasei Pharma Corporation Clinical Development Center","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Hamamatsu","state":"Shizuoka","country":"Japan","geoPoint":{"lat":34.7,"lon":137.73333}},{"city":"Fukui","country":"Japan","geoPoint":{"lat":36.06443,"lon":136.22257}},{"city":"Kumamoto, Kumamoto","country":"Japan","geoPoint":{"lat":32.80589,"lon":130.69182}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000006429","term":"Hemiplegia"}],"ancestors":[{"id":"D000010243","term":"Paralysis"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9205","name":"Hemiplegia","asFound":"Hemiplegia","relevance":"HIGH"},{"id":"M12847","name":"Paralysis","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}